Investments

Societes

Presentation

Anza has developed a very unique technology exploiting the bacterium Listeria.  The bacteria is used in either an attenuated or “Killed But Metabolically Active” (KBMA) form, to elicit a immune response – both innate and acquired – and additionally to deliver the protein/peptide at the required location to engender the response.
Concorde, USA

Click here for the site of Sofinnova Ventures, our sister firm in San Francisco http://www.sofinnova.com